The Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA) is conducting market research on all qualified vendors of business intelligence software for influenza vaccine supply chain [Read more]
The U.S. Centers for Disease Control and Prevention is seeking a vendor who can obtain anonymous pre- and post-immunization sera from specified age-groups of Europeans. The study must be conducted in a [Read more]
AbCellera Biologics Inc. this week announced that it was awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to develop rapid countermeasures against viral outbreaks. Under DARPA’s Pandemic Prevention Platform (P3) [Read more]
Researchers at Texas Biomedical Research Institute in San Antonio have been awarded a $2 million dollar contract by the makers of ZMapp, Mapp Biopharmaceutical, Inc., to further test this promising new therapeutic [Read more]
To enable a rapid vaccine response during a severe outbreak or pandemic, there is a pressing need for a potency test that is rapid and has sufficient sensitivity to track potency in [Read more]
The Defense Advanced Research Projects Agency (DARPA) launched the Pandemic Prevention Platform (P3) program in 2017, with the eventual goal of halting the spread of any infectious disease outbreak before it can escalate into a pandemic. [Read more]
In support of rapid development of safe and effective radiological/nuclear medical countermeasures for clinical use under emergency situations, the National Institute of Allergy and Infectious Diseases (NIAID) is seeking new or renewal [Read more]
The National Opinion Research Center at the University of Chicago has been awarded a contract in support of the National Center for Immunizations and Respiratory Diseases (NCIRD) Influenza Division of the Centers [Read more]
The Defense Logistics Agency Troop Support is soliciting for the supply of Injectable Influenza Vaccine for the 2018-2019 flu season. Approximately 3.6 million doses are included in this requirement. The vaccines shall [Read more]
Bavarian Nordic announced on Feb. 6 the results of a successful Phase 3 clinical trial led by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) that demonstrated the safety and [Read more]
© 2018 Global Biodefense